IRB #

STUDY00021797

Title

A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers

Principal Investigator

Emerson Chen

Study Purpose

The purpose of this study is to learn what effects the study drug, ZW25, has on the body and on cancer cells.

Medical Condition(s)

HER2 Biliary Tract Cancer

Eligibility Criteria

Male or Female at least 18 years or older
Must have HER2 biliary tract cancer

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

You can remain in the study as long as you are not getting worse or having bad side effects. After you finish the study, the study team will continue to follow your condition by phone calls every 3 months.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080

Sponsor

Zymeworks

Recruitment End

12/31/2021

Compensation Provided

No


Go Back